XLIFE-SCIENCES-AG
8.1.2021 09:10:26 CET | Business Wire | Press release
Xlife Sciences AG has reached a licensing agreement with the biotech firm Baliopharm AG, located in Basel. According to the agreement, Xlife Sciences AG will receive 10% of future income from license fees of Baliopharm AG. The Basel-based company is a leader in innovative antibody therapies for the treatment of acute and chronic inflammatory diseases.
According to the concluded licensing agreement with Baliopharm AG, Xlife Sciences AG will receive 10% of all future licensing income up to a maximum of 300 million euros. This applies to the company's entire line of active ingredients. Xlife Sciences AG thus participates directly in the future success and innovative strength of a leading biotech company in the field of antibody therapies with this transaction.
On the 18th of December, Baliopharm AG received the approval to start Phase I of medical drug Atrosimab for the treatment of Non-Alcoholic SteatoHepatitis (NASH) by the Australian Healthcare Administration. NASH is the most frequent chronic liver disease. The Global Liver Institute estimates that there are more than 115 million people affected globally by NASH. According to the Institute, this number could double by 2030. In Germany, 1.5 to 2 million patients have at least a mild form of NASH. Under more severe circumstances, the disease can lead to irreversible liver damage (liver cirrhosis) and cannot be treated therapeutically. In this way, Baliopharm AG views this as a huge market.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
Language: |
English |
Company: |
Xlife Sciences AG |
Klausstrasse 19 |
|
8008 Zürich |
|
Switzerland |
|
Phone: |
0041 44 385 84 60 |
E-mail: |
|
Internet: |
|
ISIN: |
CH0461929603 |
WKN: |
A2PK6Z |
Listed: |
Regulated Unofficial Market in Frankfurt, Munich |
EQS News ID: |
1159182 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210108005126/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Loomis Sayles Growth Equity Strategies Team Celebrates Twenty-Year Milestones7.7.2026 16:36:00 CEST | Press release
Loomis, Sayles & Company, the century-old investment manager with nearly $418 billion in assets under management, proudly celebrates the 20-year anniversaries of the Loomis Sayles Large Cap Growth and the Loomis Sayles All Cap Growth strategies, as well as a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm’s Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707992418/en/ Celebrating 20 Years of The Power of Active Management Done Right GES is a cohesive team with 20 years of alpha generation and a long-term, private equity approach to investing. Under Aziz Hamzaogullari’s leadership since 2010, assets under management for GES have grown from $1.9 billion to $98.2 billion
Integral Ad Science Appoints Lidiane Jones Chief Executive Officer7.7.2026 15:35:00 CEST | Press release
Accomplished AI and technology executive to lead IAS's next phase of innovation and growth; Lisa Utzschneider to serve as Special Advisor to the Board through year-end Integral Ad Science (IAS), one of the world's most trusted media quality companies, today announced the appointment of Lidiane Jones as Chief Executive Officer, effective immediately. Jones succeeds Lisa Utzschneider, who led IAS for more than seven years and will remain with the company as Special Advisor to the Board through the end of 2026 to support a seamless transition. Utzschneider will also serve as a Special Advisor to Novacap and their portfolio companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707780892/en/ Lidiane Jones: Integral Ad Science CEO, Photo Credit: Pamela Hanson The appointment reflects IAS's long-term strategic vision for the future of digital advertising. As AI transforms how media is planned, bought, measured, and optimized
Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough7.7.2026 15:00:00 CEST | Press release
Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in accelerating drug development timelines. Building on proven results in clinical reporting, where the collaboration has achieved up to first-draft clinical study reports (CSRs), the teams have now successfully applied similar AI capabilities to nonclinical data through high-quality parsing of raw and SEND datasets in a proof-of-concept. This advancement aligns with the Altasciences Acceleration Platform, designed to fast-track drug development across the early-phase development continuum. “This milestone reflects the power of in
SS&C Expands Tokenized Investment Capabilities with Digital Cash Settlement7.7.2026 15:00:00 CEST | Press release
Building on live tokenized fund issuance and distribution capabilities, SS&C extends its innovation roadmap to support the next stage of digital investment markets SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced plans to enable digital cash settlement for tokenized investment transactions using regulated forms of digital cash, including stablecoins and tokenized commercial bank deposits. The announcement builds on the successful launch of SS&C's live tokenized fund issuance and distribution capabilities earlier this year following the acquisition of Calastone in 2025. SS&C already enables asset managers to bring tokenized versions of traditional investment funds to market through the infrastructure and connectivity they already use, helping bridge traditional and digital investment markets. As interest in tokenized investment products continues to grow, the market is increasingly looking beyond tokenization towards the infrastructure needed to support digital transactio
Gurobi Launches Intelligence Hub to Deliver AI-Guided Workflows Across the Optimization Lifecycle7.7.2026 15:00:00 CEST | Press release
The Hub introduces specialized AI agents designed to make optimization more accessible for all users. Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the launch of the Gurobi Intelligence Hub, the new home for Gurobi’s AI-powered optimization agents. The Intelligence Hub is designed to help users build, understand, troubleshoot, and interact with optimization models more effectively. Together, the Hub’s specialized agents leverage generative AI to guide users through workflows across the optimization lifecycle, creating new opportunities to make optimization more accessible, intuitive, and valuable for a broader range of users.The Modeler combines guided workflows with Gurobi’s optimization expertise to help users move from business problem to production-quality optimization model. Through an iterative process that helps refine requirements, validate assumptions, and develop acceptance tests, the Modeler gives users confidence that their model
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom